Monopar Therapeutics Reports Third Quarter 2023 Financial Results and Recent Developments
WILMETTE, Ill., Nov. 09, 2023 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (Monopar or the Company) (Nasdaq:MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced third quarter 2023 financial results and summarized recent developments.
Related news for (MNPR)
- Monopar Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes
- Monopar Therapeutics Reports First Quarter 2025 Financial Results and Recent Developments
- Monopar Therapeutics Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants
- monopar therapeutics inc. announces closing of $19.2 million public offering of common stock
- monopar therapeutics inc. announces pricing of $19.2 million public offering of common stock